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Background: Chlamydia is the most commonly reported bacterial sexually transmitted infection in Europe. The objective of the Screening for
Chlamydia in Europe (SCREen) project was to describe current and planned chlamydia control activities in Europe.Methods: The authors sent
a questionnaire asking about different aspects of chlamydia epidemiology and control to public health and clinical experts in each country in
2007. The principles of sexually transmitted infection control were used to develop a typology comprising five categories of chlamydia
control activities. Each country was assigned to a category, based on responses to the questionnaire. Results: Experts in 29 of 33 (88%) invited
countries responded. Thirteen of 29 countries (45%) had no current chlamydia control activities. Six countries in this group stated that there
were plans to introduce chlamydia screening programmes. There were five countries (17%) with case management guidelines only. Three
countries (10%) also recommended case finding amongst partners of diagnosed chlamydia cases or people with another sexually transmitted
infection. Six countries (21%) further specified groups of asymptomatic people eligible for opportunistic chlamydia testing. Two countries
(7%) reported a chlamydia screening programme. There was no consistent association between the per capita gross domestic product of a
country and the intensity of chlamydia control activities (P=0.816). Conclusion: A newly developed classification system allowed the breadth
of ongoing national chlamydia control activities to be described and categorized. Chlamydia control strategies should ensure that clinical
guidelines to optimize chlamydia diagnosis and case management have been implemented before considering the appropriateness of
screening programmes.
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Introduction
Sexually transmitted Chlamydia trachomatis is the most frequently reportedof all notifiable infections in several industrialized countries and reported
diagnoses are increasing.1–3 Chlamydia prevalence is highest in women <25
years and men <30 years: 2–6% of adults in the general population in
high-income countries are estimated to be infected,4–8 and most are asymp-
tomatic.8 Untreated chlamydia can cause infertility and ectopic pregnancy in
women and epididymo-orchitis in men.9 Chlamydia is associated with
adverse pregnancy and neonatal outcomes and facilitation of HIV
transmission.9
The general principles of sexually transmitted infection control include
early diagnosis and effective treatment of infected cases and, through
partner notification, sexual partners who might have infected the case
or might have been exposed to infection.10 Screening of asymptomatic
individuals is frequently recommended as an intervention11–14 since
>95% of chlamydia-infected women and men in population-based
surveys are asymptomatic.8 The ways in which case management,
screening, surveillance and other components of chlamydia control are
incorporated into communicable disease control programmes in different
countries are, however, not well understood. The objectives of this study
were to describe the range and intensity of existing and planned
chlamydia control activities in Europe.
Methods
The Screening for Chlamydia Review in Europe (SCREen) project was
conducted between November 2006 and January 2008. The methods and
results are described in detail in a technical report.15 The project was
commissioned by the European Centre for Disease Prevention and
Control (ECDC) to investigate public health activities that contribute
to the control of sexually transmitted genital C. trachomatis in Europe
and to aid development of guidance for European Union Member
States.16 We invited all Member and candidate states of the European
Union (as of November 2006) and countries in the European Free Trade
Association (EFTA); Iceland, Liechtenstein, Norway and Switzerland.
We designed a structured questionnaire in English, which asked about:
the existence, audience and content of guidelines on the management of
genital chlamydia; laws and policies about sexually transmitted infection
control; diagnosis of chlamydia; surveillance of chlamydia and its com-
plications; the organization of and payment for clinical services; existing
or planned screening programmes; and publications about chlamydia
prevalence and sexual behaviour, if available. These data were supple-
mented by inclusion in the database of economic and demographic in-
formation on each country.
The questionnaire was sent in January 2007 by e-mail or post to public
health and clinical experts in each country, identified through lists of
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representatives of the European Surveillance for Sexually Transmitted
Infections network and the International Union against Sexually
Transmitted Infections Europe group. They were asked to involve
experts with specialist knowledge if they themselves did not know the
answers. We sent multiple reminders. Country representatives reviewed
the preliminary analysis; the data used in this report include all re-
sponses, amendments and clarifications received by 14 January 2008.
We developed a system for classifying chlamydia control activities at
the country level using items from the questionnaire and the principles of
sexually transmitted infection control.10 The resulting categories
described criteria that required increasing technical and organizational
capacity for implementation (Supplementary Web table S1). Case
management for diagnosed cases was assessed from guidelines, which
we considered an essential requirement for delivering and monitoring
consistent care. Case finding for partners of diagnosed cases was
considered a requirement for chlamydia control and documentation of
this in guidelines was required. We made two categories for activities
aimed at early chlamydia detection. Opportunistic chlamydia testing
was defined as testing offered to groups of asymptomatic patients
attending health-care settings, where the onus is on the health profes-
sional to repeat the offer at regular intervals.17 A chlamydia screening
programme was defined as organized systematic screening as part of the
public health system. We assessed screening programme activities against
a published checklist.18
Questionnaire data were reviewed by two pairs of project team
members. Each pair examined one half of the participating countries
and each member of the pair independently assigned the relevant
country to a category. No reviewer assessed data from their own
country. Discrepancies were resolved by discussion or the decision of a
third person. Where the activities of a country spanned different
categories, we assigned the lowest.
Data were entered into an Access (Microsoft Office) database. The data
were summarized descriptively. We made a limited number of statistical
comparisons using Kruskal–Wallis tests for non-normally distributed
continuous data and chi-squared tests for categorical data. We use the
term ‘sexually transmitted infection specialists’ to refer to all such spe-
cialists, including dermatovenereologists and genitourinary medicine
specialists.
Results
Of the 33 invited countries, we received responses from more than 80
experts in a total of 29 (88%) countries. We could not collect information
from Croatia, Cyprus, Poland and Slovakia.
Clinical practice guidelines
Among 29 participating countries, experts in 17 reported 32 sets of
guidelines for the management of genital chlamydial infection endorsed
by a nationally recognized professional organization (table 1). Three
countries were in the process of publishing or preparing guidelines and
nine had no guideline. Ten countries had a guideline intended for all
practitioners. In four of these different professional groups had developed
separate guidelines (table 1). The content of different guidelines in the
same country was sometimes inconsistent. In The Netherlands, for
example, a guideline for all practitioners is published by the Institute
for Healthcare Quality. There are separate guidelines for primary care,
sexually transmitted infection specialists, gynaecologists and municipal
health service staff. The eligible age groups and recommendations
about repeat testing differ. Audit19 of adherence to guidelines was only
practised in genitourinary medicine clinics in the UK.
Availability of chlamydia testing
Chlamydia testing was available in many settings, including all
26 participating countries with specialist clinics and gynaecology clinics
in all 29 countries (table 2). In 17 countries, gynaecology clinics were the
most likely setting for chlamydia testing. Chlamydia testing was also available
in most countries in urology, primary care and family planning clinics. In
five countries, chlamydia testing kits could be bought in pharmacies or
other over-the-counter outlets. Settings where chlamydia testing could be
carried out were not always covered by case management guidelines. In 16/29
countries where chlamydia testing was available in gynaecology clinics,
there was no clinical guideline, i.e. no guideline applicable to all practi-
tioners. In nine of these countries, this was the most common setting for
chlamydia testing. Nearly half (12/26) of countries with specialist sexually
transmitted infection clinics did not have a guideline for these practition-
ers (table 2).
Partner notification
Of 32 guidelines, recommendations about partner notification were
included in 26. In most non-specialist settings where chlamydia testing
was offered, partner notification was reported to be initiated by the
Table 1 Coverage of chlamydia case management guidelines in Europe
Guideline audience (N=29) Countries
Single guideline for all practitioners
(n=6)
Estonia, Hungary, Iceland,
Lithuania, Norway, Romania
Guideline for all practitioners PLUS
separate specialist guidelinesa
(n=4)
Belgium, Czech Republic,
Sweden, The Netherlands
Sexually transmitted infection
specialists only (n=3)
Austria, France, Italy
Guideline for sexually transmitted
infection specialists PLUS separate
specialist guidelinesb (n=2)
Latvia, UK
Primary care practitioners only (n=1) Denmark
Antenatal clinics/urology only (n=1) Germany
Guideline in preparationc (n=3) Bulgaria, Finland, Greece
No guidelinec (n=9) Ireland, Liechtenstein,
Luxembourg, Malta, Portugal,
Slovenia, Spain, Switzerland,
Turkey
a: Includes any combination of dermatovenereology, primary care, gy-
naecology, youth clinics, municipal health services
b: Includes gynaecology (Latvia), tests being done for chlamydia
screening programme (UK, England only)
c: As of January 2008. Adapted from Table 5, Ref. 15.
Table 2 Availability of chlamydia testing and of clinical guidelines in
specified settings
Setting Chlamydia
testing
available, n
Most
common
setting, na
Practitioners
not covered
by guidelineb,
n (%)
Gynaecology 29 17 16 (55)
Sexually transmitted
infection clinic
26 2 12 (46)
Urology 25 3 17 (68)
Primary care 23 11 13 (57)
Family planning 22 2 13 (62)
Internal medicine 11 0 7 (64)
Emergency department 10 0 6 (60)
Pharmacy 5 0 Not knownc
a: Countries could rank more than one setting as the most likely place
for testing, so total is more than the number of countries
b: Denominator is number of countries in which chlamydia testing is
available at each setting
c: Questionnaire did not ask whether guidelines covered non-clinical
settings. Reproduced from Table 8, Ref. 15.
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physician in the clinic. In a minority of countries respondents explicitly
noted that no partner notification took place. This was most frequently
reported about family planning clinics (5/22).
Laboratory diagnosis
Nucleic acid amplification tests for chlamydia diagnosis, which are the
most accurate but also the most expensive assays,20 were available to
some extent in all but one country (Bulgaria) but were not always
available for routine testing. The percentage of tests analysed using
nucleic acid amplification tests was <10% in five countries, 10–49% in
four, 50–90% in five and >90% in 11. There was statistical evidence of an
association between increasing per capita gross domestic product (GDP)
and the level of nucleic acid amplification testing (P = 0.003). Countries
in which laboratories took part in diagnostic quality assurance schemes
were more likely to also have clinical guidelines for at least one group of
health professionals (15/19) than those that did not (4/10, P = 0.036).
Surveillance for chlamydia
Most countries (25/29) reported some system for surveillance of
chlamydia infections. The most common method was a statutory require-
ment for reporting of all laboratory diagnosed cases (15 countries). Seven
countries conducted surveillance in selected sentinel sites or with
reporting only from sexually transmitted infection clinics. Nine
countries did not publish surveillance data about chlamydia and in
three countries reporting from laboratories was voluntary. The
recorded rate of diagnosed chlamydia differed markedly between
countries, even within the group where reporting of diagnosed cases
was reported to be compulsory (figure 1).
Categorization of chlamydia control activities
The category to which each country was assigned is shown in table 3. There
was no consistent association between median GDP across categories of
chlamydia control activities (P = 0.816). The group with no organized
activity included countries in Europe with the highest (Liechtenstein
and Luxembourg) and lowest (Turkey and Bulgaria) per capita GDP.
No organized chlamydia control activity
The largest category (13/29, 45%) was of countries that were defined as
having with no current activities because they did not have a nationally
recommended guideline, or because the availability of services was very
limited (table 3). Six countries in this group stated plans to introduce
chlamydia screening programmes.
Case management for diagnosed chlamydia
There were five countries (17%) in this group (table 3). The guidelines in
Lithuania and the Czech Republic applied to all practitioners. They
applied only to sexually transmitted infection specialists in Austria and
Italy, and gynaecologists and urologists in Germany. Chlamydia testing in
these countries was usually, however, widely available in other clinical
settings (table 1).
Case finding for partners of infected cases
Three countries (10%) were included in this category (table 3). Although
case management guidelines for other countries were reported to cover
partner notification, we only included those that explicitly stated that
partners of diagnosed chlamydia cases or people with another sexually
transmitted infection should be offered chlamydia testing.
Opportunistic chlamydia testing
Six countries (21%) specified groups of asymptomatic people eligible for
chlamydia testing at selected settings (table 3). The groups offered testing
differed between countries but most commonly included sexually active
adolescents and young adults with multiple sexual partners or a recent
change of partner, and women undergoing uterine instrumentation. In
Sweden, opportunistic chlamydia testing takes place across the country in
a variety of clinical settings. Diagnosis and treatment are free and partner
notification is mandatory.21
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Figure 1 Rate of diagnosed chlamydia cases per 100 000 population in Europe, 2005 or 2006. Figure includes data from all countries that provided
data about reported chlamydia cases in 2005 or 2006. Numerator is the number of diagnosed chlamydia cases reported; denominator is the total
mid-year population of the country in the year of data collection. Countries with selective reporting include those that publish data about all cases
reported from sentinel sites, including countries that report all cases diagnosed in specialist clinics. Countries with no apparent cases either did not
provide data, or did not have data available. Reproduced from Figure 4, Ref. 15
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Chlamydia screening programmes
Two countries (The Netherlands and the UK, 7%) reported a chlamydia
screening programme covering a substantial part of the population that
was ongoing or was being conducted as a pilot programme (table 3). In
the UK, chlamydia screening was introduced in England in 2003 and
rolled out across that country by the end of 2007.22 Screening tests are
offered opportunistically to sexually active women and men aged <25
years attending selected settings, depending on the area and, in some
places, through outreach activities. When assessed against the checklist
of Gray,18 most criteria were fulfilled, but the proportion of positive cases
was not accepted as a valid performance measure of chlamydia
prevalence, and incidence of complications was planned but not
implemented. The programme did not cover Scotland, Wales or
Northern Ireland. In The Netherlands, the Chlamydia Screening
Implementation project is a pilot programme in three regions of the
country, which began in March 2007.23 Chlamydia screening invitations
are delivered at yearly intervals to men and women aged 16–29 years
using population registers. Recipients request a home sampling kit
through a web-based application. In two regions, all those in the target
age group are invited; in one region eligibility is assessed by a web-based
questionnaire. The main objectives and performance measures were valid.
The programme will be evaluated using a randomized design. In both
programmes there were features that were still under development.
Nine countries reported plans to introduce chlamydia screening
programmes in the future, including six with no current chlamydia
Table 3 Level of chlamydia control activities for European countries participating in project SCREen
Country Comments
No organized chlamydia control activity (n=13)
Bulgaria Case management guideline, planned publication January 2008. Screening programme planned.
Finland Case management guideline planned for development 2008. Opportunistic programme planned.
Greece No case management guideline. Screening programme planned.
Ireland No case management guideline.
Liechtenstein No case management guideline.
Luxembourg No case management guideline. Opportunistic screening programme planned.
Malta No case management guideline.
Portugal No case management guideline.
Romania Case management guideline for all practitioners, but very limited facilities for testing in practice.
Slovenia No case management guideline. Screening programme planned.
Spain No case management guideline.
Switzerland No case management guideline.
Turkey No case management guideline. Screening programme planned.
Case management for diagnosed chlamydia cases (n=5)
Austria Case management guideline for sexually transmitted infection clinics. Chlamydia testing available in other settings but partner
notification done in primary care only.
Czech Republic Case management guideline for all practitioners deals with diagnosis but not treatment or partner notification. Partner notifi-
cation reported to be by referral to specialist clinic.
Germany Case management guideline for gynaecology (pregnant women) and urology. Chlamydia testing not done in primary care. Partner
notification reported to be done by practitioner in gynaecology (where most tests are done), urology, internal medicine, but not
in family planning clinics.
Italy Case management guideline for sexually transmitted infection clinics. Chlamydia testing for symptomatic people only. Chlamydia
testing and partner notification available in other settings.
Lithuania Case management guideline for all practitioners includes partner management, but no list of who should be offered chlamydia
testing and, in practice, said not to take place.
Case finding for partners of diagnosed chlamydia cases (n=3)
Belgium Partner management included in guideline for primary care (where most tests are done) and gynaecology. Primary care guideline
includes testing only for female partners of symptomatic men.
France Case management guideline for sexually transmitted infection clinics. Testing recommended for partners of cases with sexually
transmitted infection. Chlamydia testing available in many other settings and partner notification reported to be done by
patient referral initiated by practitioner. Screening programme planned.
Hungary Case management guideline for all practitioners, including chlamydia testing for all sexual partners of symptomatic patients with a
sexually transmitted infection. In practice, partner notification might not take place.
Opportunistic testing for selected asymptomatic individuals (n=6)
Denmark Guideline includes opportunistic chlamydia testing in primary care (where most tests are done) for asymptomatic people with
frequent sex partner change, women <26 years before intrauterine device insertion or hysterosalpingogram. Also annual postal
invitation for screening in two communities.
Estonia Guideline for all practitioners includes opportunistic testing for pregnant women and asymptomatic people with frequent sex
partner change, clients of commercial sex workers, following sexual assault.
Iceland Guideline for all practitioners includes opportunistic testing for women presenting for termination of pregnancy, egg and sperm
donors.
Latvia Opportunistic testing recommended for pregnant women. Partner management included in guideline for sexually transmitted
infection and gynaecology clinics, including chlamydia testing for partners of patients with a sexually transmitted infection.
Partner notification done by practitioner or by referral to specialist clinic.
Norway Guideline for all practitioners includes opportunistic testing for women presenting for termination of pregnancy or antenatal care,
<25 s with recent partner change, and partners of people with a sexually transmitted infection. Plans for proactive chlamydia
screening by postal invitation following randomized controlled trial in one region.
Sweden Multiple guidelines for different practitioners. Include opportunistic testing for asymptomatic people with target groups differing
between counties.
Organized chlamydia screening programme (n=2)
The Netherlands Pilot chlamydia screening programme began March 2007. Annual postal invitation for chlamydia screening to all 16–29 year olds in
three regions from September 2008.
UK (England) Opportunistic chlamydia screening offered to all sexually active <25-year-olds attending various clinical and non-clinical settings
(depending on health district). Rolled out 2003 to March 2007.
Reproduced from Table 14, Ref. 15.
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control activities (table 3). Four programmes are planned to be delivered
using an opportunistic approach (Finland, France, Greece, Luxembourg),
compared with one (Norway) planned as a proactive, register-based
programme. In four countries, the target population includes specific
groups at high risk of chlamydia such as sex workers (Greece, Turkey),
Roma (Bulgaria) and attenders at sexually transmitted infection clinics
(France, Greece).
Monitoring the outcomes of chlamydia control activities
Three countries (France, England in the UK and The Netherlands)
reported existing or planned performance targets. In England, there
were no indicators measuring the primary outcomes of the screening
programme (reduced reproductive tract complications and transmis-
sion). In The Netherlands, proposed indicators include changes in
population prevalence and pelvic inflammatory disease incidence as
well as uptake of repeated screening invitations. The specific indicators
in France were not reported. Informants from four countries that
reported plans to introduce chlamydia screening (Bulgaria, Germany,
Greece, Norway), reported that routine data about the complications of
chlamydia were not collected.
Discussion
This study identified wide variation across 29 European countries in the
range and intensity of activities that contribute to the control of sexually
transmitted chlamydia infections. Surveillance data showed the differ-
ences between countries in reported rates of diagnosed cases. Seventeen
countries had at least one guideline about the diagnosis and management
of chlamydia infections. Thirteen countries have no organized activities
aimed at chlamydia control; five have organized case management; three
undertake additional case finding activities; seven recommend opportun-
istic testing and two reported an ongoing or pilot screening programme.
A major strength of the SCREen project was the collection and
synthesis of comparable information about a wide range of sexually
transmitted infection control activities, with a high response rate. The
survey included countries in Central and Eastern Europe that are Member
States of the European Union. The involvement of informants from
different disciplines enabled collection of information about diverse
areas of policy and practice. A weakness of this study is that it only
gives a cross-sectional overview at the national level, masking potentially
important regional differences in countries with devolved funding.
Furthermore, we probably obtained more accurate information about
what is recommended than about actual practice. Despite using
structured questions, there was inevitably some room for them to be
interpreted differently by different respondents, particularly since the
questionnaire was only written in English. This might have led to mis-
classification, although we tried to obtain clarification and key informants
commented on the draft report.15 Reliability of categorization was
increased by having two assessments, but could have been improved by
having a third external assessor.
The wide range of policies and practices might reflect a lack of
agreement about the most appropriate and effective chlamydia control
measures. Reviews of the evidence available show that there are effective
tools for the prevention, diagnosis, antibiotic treatment and partner
management of sexually transmitted infections, including chlamydia.24
There is also evidence from randomized controlled trials25–27 that the
incidence of PID in women might be reduced by about half with high
uptake (64–100%) of a single round of testing and treatment. There is an
absence, however, of empirical evidence from studies with a low risk of
bias about the relationship between the intensity of chlamydia control
and the impact on transmission.28 Screening programmes are the most
organizationally demanding of control measures.18,29 This survey found
that the performance measures for the English screening programme did
not include the primary outcomes. An independent evaluation of the
English programme in 2009 also found that the programme had been
introduced without robust data about population prevalence or evidence
for the effectiveness of screening.30 The first priority for research is,
therefore, to establish the relationship between the intensity of
chlamydia control activities and their impact on chlamydia prevalence
and reproductive tract morbidity. The Dutch Chlamydia Screening
Implementation project included in this study will be the first
pragmatic population-based randomized trial worldwide to determine
whether or not the benefits of proactive register-based chlamydia
screening can be achieved and sustained over multiple rounds.23 A
randomized trial that began in 2010 in Australia will provide information
about the effectiveness of opportunistic chlamydia screening in reducing
chlamydia prevalence in 2014–15.31
A report about screening policies in European Union Member and
Applicant States included unstructured descriptions about chlamydia
screening in 2004,32 which were broadly consistent with this study. The
advantage of the present study was that we used uniform definitions that
allowed the categorization of countries. Of note, both surveys reported
that there was no organized chlamydia screening programme in Sweden
because the widespread opportunistic screening activities are not
nationally coordinated. Chlamydia screening activities have previously
been widely described as an organized programme by both Swedish33,34
and international researchers and public health organizations.35
Disease control programmes for sexually transmitted infection should
provide primary prevention and comprehensive case management.24
These are features of disease control that should be optimized 14 before
considering screening programmes.36 The consistency and quality of case
management are more likely to be assured if clinical guidelines are in
place and adherence to them is audited. It is, therefore, notable that this
study identified several countries that reported plans to introduce
screening programmes, yet had no nationally recognized guidelines for
the management of diagnosed cases or their partners. Furthermore, while
the UK was the only country in which clinical audit was a routine
practice, this took place only in genitourinary medicine clinics. The
study also showed that partner notification was not always integrated
into chlamydia case management, or was not always done even when
recommended. Partner notification efforts seem likely to be sub-
optimal if practitioners are working in settings that are not covered by
any guidelines.
The SCREen project provides baseline information about chlamydia
control activities in place in 2007 in European countries and has
informed a guidance document for European Union Member States.16
The results of this survey and the guidance document can be used to
audit progress in the development of chlamydia control strategies, with
assessment against measurable standards.19 An update of the survey
would provide valuable information to monitor changes in the
intensity of chlamydia control activities at country level, introduction
of planned activities and adoption of recommendations. Of interest,
economic resources did not seem to be associated with the priority
assigned to chlamydia control in participating countries. The results of
this survey indicate that the majority of chlamydia infections in the popu-
lations of European countries continue to go undetected with the risk of
subsequent complications and onward transmission. Chlamydia control
strategies should ensure that there are primary preventive activities and
clinical guidelines to optimize chlamydia diagnosis and case management
before considering the appropriateness of screening programmes.
Supplementary data
Supplementary data are available at Eurpub online.
Acknowledgements
The authors would like to acknowledge the contributions made by
experts in participating countries in providing data and Dr Keith
Radcliffe for contacting members of the International Union against
Sexually Transmitted Infections Europe group on our behalf. F.F.H.
was at the European Centre for Disease Prevention and Control,
Stockholm, Sweden when this project was done. A.M.H. was at the
Institute of Social and Preventive Medicine, University of Bern, Bern,
Switzerland when this project was done.
560 European Journal of Public Health
Funding
This work was funded by the European Centre for Disease Prevention and
Control, contract number ECD.290. Part of this work was undertaken at
UCLH/UCL who received a proportion of funding from the Department
of Health’s National Institute for Health Research Centres funding
scheme. We are grateful for the support of the Margaret Pyke Trust
which contributes to the programme of reproductive health research at
UCL.
Conflicts of interest: None declared.
Key points
 Chlamydia trachomatis is the most commonly notified
sexually transmitted infection in most developed countries.
 The most effective and cost-effective strategies for
controlling chlamydia transmission are not known.
 Activities that contribute to chlamydia control vary widely in
Europe, with many countries having no organized activities.
 Chlamydia control strategies should ensure that clinical
guidelines to optimize chlamydia diagnosis and case
management have been implemented before considering
the appropriateness of screening programmes.
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